<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183051</url>
  </required_header>
  <id_info>
    <org_study_id>107.197</org_study_id>
    <nct_id>NCT02183051</nct_id>
  </id_info>
  <brief_title>Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar</brief_title>
  <official_title>A Short Term Double-blind Trial to Compare the the Analgesic Efficacy and Tolerability of Meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg Oral (Quick Tablet) Versus Placebo and Ibuprofen 400 mg and 200 mg Oral in the Treatment of Pain After Surgery of the Third Molar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and
      1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg
      administered in a single dose, over an observation period of 6 hours in the treatment of pain
      after surgery of the third molar.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pain intensity differences (PID) on a visual analogue scale (VAS, 100 mm) from one hour onwards</measure>
    <time_frame>60, 90, 120, 180, 240, 300 and 360 minutes after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PID on a VAS</measure>
    <time_frame>Up to 360 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences (SPID)</measure>
    <time_frame>Up to 360 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pain decrease &gt;=50%</measure>
    <time_frame>Up to 360 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of maximum pain decrease on a VAS</measure>
    <time_frame>Up to 360 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to safety reasons</measure>
    <time_frame>Up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, nature and severity of adverse events</measure>
    <time_frame>Up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pain relief (TOTPAR) assessed by patient (Area under the pain relief-by time curve)</measure>
    <time_frame>Up to 360 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of onset of analgesic action</measure>
    <time_frame>Up to 2 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final assessment of efficacy by patient on a 4-point verbal rating scale (VRS)</measure>
    <time_frame>6 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final assessment of efficacy by investigator on a 4-point VRS</measure>
    <time_frame>2 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory values</measure>
    <time_frame>Baseline, up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the progress of healing of the extraction site</measure>
    <time_frame>3-7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of overall tolerability on a 4-point rating scale</measure>
    <time_frame>Day 7 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment of overall tolerability on a 4-point rating scale</measure>
    <time_frame>Day 7 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief assessed by patient on a 5-point VRS</measure>
    <time_frame>Up to 360 minutesafter drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to inadequate efficacy</measure>
    <time_frame>Up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam 3.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam 1.875 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 7.5 mg</intervention_name>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 3.75 mg</intervention_name>
    <arm_group_label>Meloxicam 3.75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 1.875 mg</intervention_name>
    <arm_group_label>Meloxicam 1.875 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 200 mg</intervention_name>
    <arm_group_label>Ibuprofen 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
    <arm_group_label>Meloxicam 3.75 mg</arm_group_label>
    <arm_group_label>Meloxicam 1.875 mg</arm_group_label>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <arm_group_label>Ibuprofen 200 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 15 mg</intervention_name>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg</intervention_name>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or above

          -  Patients undergoing removal of one impacted mandibular third molar under local
             anesthesia. (Short duration anaesthetics will be allowed, i.e. mepivacaine 3% in Italy
             and Spain and xylocaine in USA, both without vasoconstrictors) Only patients with type
             of inclusion II to IV have to be included (type II, molar in the submucosa; type III,
             molar partially included in the bone; type IV, molar fully included in the bone)

          -  Assessment of pain must be at least 50 mm on a 100 mm visual analogue scale (VAS)

          -  Patient informed consent in accordance with local legislation.

        Exclusion Criteria:

          -  Type I of inclusion (molar partially or totally erupted)

          -  Known or suspected hypersensitivity to trial drug or their excipients, analgesics,
             antipyretics or nonsteroidal antiinflammatory drug (NSAIDs)

          -  Any clinical evidence of active peptic ulceration during the last six month

          -  Recurrent ulcers

          -  Pregnancy or breast feeding

          -  Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration
             of aspirin or NSAIDs

          -  Concomitant treatment with anti-coagulants (including heparin), lithium

          -  Concomitant administration of other anti inflammatory or analgesic agents

          -  Administration of any drug with analgesic properties in the 24 h previous to the
             administration of the study drug, except the local anesthetic for the surgery

          -  Administration of any antibiotics

          -  Significant perioperative complication judged by the oral surgeon

          -  Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, hematological
             disease (including bleeding disorders), mental disturbance, ulcerative colitis

          -  Any other disease that could interfere with the evaluation of efficacy and safety

          -  Participation in another clinical trial during this study or during the previous month

          -  Previous participation in this trial

          -  Patient unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

